Bioventus’ (BVS) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Bioventus (NASDAQ:BVS) in a report issued on Monday,Benzinga reports. Cantor Fitzgerald currently has a $15.00 price target on the stock.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings upgraded Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 6th. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $16.80.

Bioventus Stock Performance

Shares of Bioventus stock opened at $14.68 on Monday. The business’s fifty day simple moving average is $11.67 and its 200 day simple moving average is $10.05. The firm has a market capitalization of $1.23 billion, a P/E ratio of 19.07, a price-to-earnings-growth ratio of 1.82 and a beta of 0.63. Bioventus has a 12 month low of $6.26 and a 12 month high of $15.89. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. The business had revenue of $153.21 million for the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, analysts anticipate that Bioventus will post 0.79 EPS for the current year.

Hedge Funds Weigh In On Bioventus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd increased its stake in shares of Bioventus by 17,156.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after purchasing an additional 5,490 shares in the last quarter. Diversified Trust Co purchased a new position in Bioventus in the 1st quarter valued at approximately $100,000. Prelude Capital Management LLC bought a new stake in Bioventus during the 3rd quarter valued at $74,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Bioventus during the third quarter worth $78,000. Finally, Brooklyn Investment Group bought a new position in shares of Bioventus in the fourth quarter worth $91,000. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.